The Labyrinthin Antigen
A paradigm shift is currently underway on the relationship between cancer treatment markers and current cancer therapies.
The antigen Labyrinthin, recognized by the mouse monoclonal antibody MCA 44-3A6, is a prime example of such a marker because it serves as a pan-adenocarcinoma marker that is expressed on the surface of essentially all adenocarcinomas, including lung, breast, prostate, colorectal, prostate, stomach, liver, pancreatic, and ovarian cancer, but not in normal cells nor other types of cancers.
Adenocarcinomas represent over 45% of all new cancer cases and cancer deaths. There are approximately 7.9 million new adenocarcinoma patients each year.
Although a range of immunotherapy approaches exist, our vaccine is targeted towards Labyrinthin-based peptides because, unlike the cancer targets for current therapies, it is both a broad and selective target and it is not a normally occurring target that is overexpressed.
We founded our company to build on early monoclonal antibody and vaccine innovations to pioneer new immunotherapies while making our product candidates available to a broader patient population.
The LabVax Platform
In 2003, we engineered one of the earliest known synthetic peptide vaccines which was approved by the WHO for a Phase I/II in-human clinical trial. Our most recent synthetic vaccine, LabVax 2.0, is a labyrinthin-based peptide complex vaccine and is specifically designed to elicit both a humoral immune response (B-Cell) and a cell mediated immune response (T-Cell).
The idea is for the body to engage its own immune system to produce antibodies that target and locate Labyrinthin-positive cancer cells to initiate a process that both prevents tumor growth and kill existing tumor cells.